SCHEMBL24253527

SCHEMBL24253527

Fc1ccc(-c2cccc(Cl)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.45
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RAB9A P51151 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
NFE2L2 Q16236 1/20 0.41
ALOX5 P09917 1/20 0.41
SCN9A Q15858 5/20 0.41
HSD17B14 Q9BPX1 1/20 0.41
NPC1 O15118 2/20 0.41
ATM Q13315 1/20 0.41
GRM5 P41594 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
TXN P10599 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424039 1.00 JAK2 (0.45) JAK2ALDH1A1MAPTPOLBHPGD
Formamide SCHEMBL29261721 0.89 NFE2L2 (0.42) JAK2ALDH1A1MAPTRAB9AL3MBTL1
SCHEMBL4348467 0.84 RAB9A (0.59) ALDH1A1MAPTPOLBHPGDHSD17B10
SCHEMBL6344776 0.82 RAB9A (0.56) ALDH1A1MAPTPOLBHPGDHSD17B10
SCHEMBL1662450 0.80 MEN1 (0.68) JAK2ALDH1A1MAPTPOLBHPGD
SCHEMBL1636596 0.79 MEN1 (0.52) JAK2ALDH1A1MAPTPOLBHPGD
SCHEMBL27832833 0.79 MAPT (0.72) JAK2ALDH1A1MAPTPOLBHPGD
SCHEMBL16538337 0.79 SCN9A (0.46) JAK2ALOX5SCN9A
SCHEMBL7009235 0.78 ALDH1A1 (0.46) ALDH1A1MAPTPOLBHPGDHSD17B10
SCHEMBL31008541 0.77 RAB9A (0.47) JAK2ALDH1A1MAPTPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092042-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2025-03-20 US disclosed
US-12157737-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2024-12-03 US disclosed
CN-117945992-A Preparation method of fluopicolide 宁夏宁东泰和化学科技有限公司 2024-04-30 CN disclosed
US-20240043425-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2024-02-08 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
EP-4196478-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2023-06-21 EP disclosed
CN-116157404-A Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof 诺华股份有限公司 2023-05-23 CN disclosed
WO-2022034529-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2022-02-17 WO disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157737-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 JAK2 414/4885ALDH1A1 323/4885MAPT 4450/4885
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 JAK2 414/4885ALDH1A1 323/4885MAPT 4450/4885
US-20240043425-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 JAK2 414/4885ALDH1A1 323/4885MAPT 4450/4885
US-20250092042-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, PKD1, PKD2 JAK2 489/4885ALDH1A1 200/4885MAPT 4190/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 JAK2 414/4885ALDH1A1 323/4885MAPT 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.